Co-regulation of innate and adaptive immune responses induced by ID93+GLA-SE vaccination in humans.

Autor: Fiore-Gartland A; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, United States., Srivastava H; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, United States., Seese A; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, United States., Day T; Infectious Diseases and Vaccines, Innovative Medicine, Johnson & Johnson, Leiden, Netherlands., Penn-Nicholson A; Foundation for Innovative New Diagnostics (FIND), Geneva, Switzerland., Luabeya AKK; South African Tuberculosis Vaccine Initiative (SATVI), Institute of Infectious Disease & Molecular Medicine and Department of Pathology, University of Cape Town, Cape Town, South Africa., Du Plessis N; Department of Science and Technology/National Research Foundation (DST-NRF) Centre of Excellence for Biomedical Tuberculosis Research, South African Medical Research Council Centre for Tuberculosis Research, Biomedical Research Institute, Division of Molecular Biology and Human Genetics, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa., Loxton AG; Department of Science and Technology/National Research Foundation (DST-NRF) Centre of Excellence for Biomedical Tuberculosis Research, South African Medical Research Council Centre for Tuberculosis Research, Biomedical Research Institute, Division of Molecular Biology and Human Genetics, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa., Bekker LG; The Desmond Tutu Human Immunodeficiency Virus (HIV) Centre, University of Cape Town, Cape Town, South Africa., Diacon A; TASK, Cape Town, South Africa., Walzl G; Department of Science and Technology/National Research Foundation (DST-NRF) Centre of Excellence for Biomedical Tuberculosis Research, South African Medical Research Council Centre for Tuberculosis Research, Biomedical Research Institute, Division of Molecular Biology and Human Genetics, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa., Sagawa ZK; Access to Advanced Health Institute, Seattle, WA, United States., Reed SG; HDT Bio Corporation, Seattle, WA, United States., Scriba TJ; South African Tuberculosis Vaccine Initiative (SATVI), Institute of Infectious Disease & Molecular Medicine and Department of Pathology, University of Cape Town, Cape Town, South Africa., Hatherill M; South African Tuberculosis Vaccine Initiative (SATVI), Institute of Infectious Disease & Molecular Medicine and Department of Pathology, University of Cape Town, Cape Town, South Africa., Coler R; Seattle Children's Research Institute, Center for Global Infectious Disease Research, Seattle Children's, Seattle, WA, United States.; Department of Pediatrics, University of Washington School of Medicine, Seattle, WA, United States.; Department of Global Health, University of Washington, Seattle, WA, United States.

Publikováno v: Frontiers in immunology [Front Immunol] 2024 Sep 24; Vol. 15, pp. 1441944. Date of Electronic Publication: 2024 Sep 24 (Print Publication: 2024).

Safety and immunogenicity of the adjunct therapeutic vaccine ID93 + GLA-SE in adults who have completed treatment for tuberculosis: a randomised, double-blind, placebo-controlled, phase 2a trial.

Autor: Day TA; Infectious Disease Research Institute, Seattle, WA, USA., Penn-Nicholson A; South African Tuberculosis Vaccine Initiative (SATVI), Institute of Infectious Disease & Molecular Medicine and Division of Immunology, Department of Pathology, University of Cape Town, Cape Town, South Africa., Luabeya AKK; South African Tuberculosis Vaccine Initiative (SATVI), Institute of Infectious Disease & Molecular Medicine and Division of Immunology, Department of Pathology, University of Cape Town, Cape Town, South Africa., Fiore-Gartland A; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA., Du Plessis N; DST-NRF Centre of Excellence for Biomedical Tuberculosis Research, South African Medical Research Council Centre for Tuberculosis Research, Division of Molecular Biology and Human Genetics, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa., Loxton AG; DST-NRF Centre of Excellence for Biomedical Tuberculosis Research, South African Medical Research Council Centre for Tuberculosis Research, Division of Molecular Biology and Human Genetics, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa., Vergara J; Infectious Disease Research Institute, Seattle, WA, USA., Rolf TA; Infectious Disease Research Institute, Seattle, WA, USA., Reid TD; South African Tuberculosis Vaccine Initiative (SATVI), Institute of Infectious Disease & Molecular Medicine and Division of Immunology, Department of Pathology, University of Cape Town, Cape Town, South Africa., Toefy A; South African Tuberculosis Vaccine Initiative (SATVI), Institute of Infectious Disease & Molecular Medicine and Division of Immunology, Department of Pathology, University of Cape Town, Cape Town, South Africa., Shenje J; South African Tuberculosis Vaccine Initiative (SATVI), Institute of Infectious Disease & Molecular Medicine and Division of Immunology, Department of Pathology, University of Cape Town, Cape Town, South Africa., Geldenhuys H; South African Tuberculosis Vaccine Initiative (SATVI), Institute of Infectious Disease & Molecular Medicine and Division of Immunology, Department of Pathology, University of Cape Town, Cape Town, South Africa., Tameris M; South African Tuberculosis Vaccine Initiative (SATVI), Institute of Infectious Disease & Molecular Medicine and Division of Immunology, Department of Pathology, University of Cape Town, Cape Town, South Africa., Mabwe S; South African Tuberculosis Vaccine Initiative (SATVI), Institute of Infectious Disease & Molecular Medicine and Division of Immunology, Department of Pathology, University of Cape Town, Cape Town, South Africa., Bilek N; South African Tuberculosis Vaccine Initiative (SATVI), Institute of Infectious Disease & Molecular Medicine and Division of Immunology, Department of Pathology, University of Cape Town, Cape Town, South Africa., Bekker LG; Desmond Tutu HIV Centre, University of Cape Town, Cape Town, South Africa., Diacon A; TASK Applied Sciences, Cape Town, South Africa., Walzl G; DST-NRF Centre of Excellence for Biomedical Tuberculosis Research, South African Medical Research Council Centre for Tuberculosis Research, Division of Molecular Biology and Human Genetics, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa., Ashman J; Infectious Disease Research Institute, Seattle, WA, USA., Frevol A; Infectious Disease Research Institute, Seattle, WA, USA., Sagawa ZK; Infectious Disease Research Institute, Seattle, WA, USA., Lindestam Arlehamn C; Center for Infectious Disease, Division of Vaccine Discovery, La Jolla Institute for Immunology, La Jolla, CA, USA., Sette A; Center for Infectious Disease, Division of Vaccine Discovery, La Jolla Institute for Immunology, La Jolla, CA, USA., Reed SG; Infectious Disease Research Institute, Seattle, WA, USA., Coler RN; Infectious Disease Research Institute, Seattle, WA, USA; Department of Global Health, University of Washington, Seattle, WA, USA; PAI Life Sciences, Seattle, WA, USA., Scriba TJ; South African Tuberculosis Vaccine Initiative (SATVI), Institute of Infectious Disease & Molecular Medicine and Division of Immunology, Department of Pathology, University of Cape Town, Cape Town, South Africa., Hatherill M; South African Tuberculosis Vaccine Initiative (SATVI), Institute of Infectious Disease & Molecular Medicine and Division of Immunology, Department of Pathology, University of Cape Town, Cape Town, South Africa. Electronic address: mark.hatherill@uct.ac.za.

Publikováno v: The Lancet. Respiratory medicine [Lancet Respir Med] 2021 Apr; Vol. 9 (4), pp. 373-386. Date of Electronic Publication: 2020 Dec 08.

Regional changes in tuberculosis disease burden among adolescents in South Africa (2005-2015).

Autor: Bunyasi EW; South African Tuberculosis Vaccine Initiative, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa., Mulenga H; South African Tuberculosis Vaccine Initiative, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa., Luabeya AKK; South African Tuberculosis Vaccine Initiative, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa., Shenje J; South African Tuberculosis Vaccine Initiative, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa., Mendelsohn SC; South African Tuberculosis Vaccine Initiative, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa., Nemes E; South African Tuberculosis Vaccine Initiative, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa., Tameris M; South African Tuberculosis Vaccine Initiative, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa., Wood R; Desmond Tutu HIV Center, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa., Scriba TJ; South African Tuberculosis Vaccine Initiative, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa., Hatherill M; South African Tuberculosis Vaccine Initiative, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa.

Publikováno v: PloS one [PLoS One] 2020 Jul 01; Vol. 15 (7), pp. e0235206. Date of Electronic Publication: 2020 Jul 01 (Print Publication: 2020).

Temporal trends in the prevalence of Mycobacterium tuberculosis infection in South African adolescents.

Autor: Bunyasi EW; South African Tuberculosis Vaccine Initiative, Institute of Infectious Disease & Molecular Medicine and Division of Immunology, Department of Pathology, University of Cape Town, Cape Town., Geldenhuys H; South African Tuberculosis Vaccine Initiative, Institute of Infectious Disease & Molecular Medicine and Division of Immunology, Department of Pathology, University of Cape Town, Cape Town., Mulenga H; South African Tuberculosis Vaccine Initiative, Institute of Infectious Disease & Molecular Medicine and Division of Immunology, Department of Pathology, University of Cape Town, Cape Town., Shenje J; South African Tuberculosis Vaccine Initiative, Institute of Infectious Disease & Molecular Medicine and Division of Immunology, Department of Pathology, University of Cape Town, Cape Town., Luabeya AKK; South African Tuberculosis Vaccine Initiative, Institute of Infectious Disease & Molecular Medicine and Division of Immunology, Department of Pathology, University of Cape Town, Cape Town., Tameris M; South African Tuberculosis Vaccine Initiative, Institute of Infectious Disease & Molecular Medicine and Division of Immunology, Department of Pathology, University of Cape Town, Cape Town., Nemes E; South African Tuberculosis Vaccine Initiative, Institute of Infectious Disease & Molecular Medicine and Division of Immunology, Department of Pathology, University of Cape Town, Cape Town., Mahomed H; Department of Health, Western Cape and Division of Community Health, Stellenbosch University, Stellenbosch, South Africa., Rozot V; South African Tuberculosis Vaccine Initiative, Institute of Infectious Disease & Molecular Medicine and Division of Immunology, Department of Pathology, University of Cape Town, Cape Town., Wood R; The Desmond Tutu HIV Centre, Institute of Infectious Disease & Molecular Medicine, University of Cape Town, Cape Town, South Africa., Scriba T; South African Tuberculosis Vaccine Initiative, Institute of Infectious Disease & Molecular Medicine and Division of Immunology, Department of Pathology, University of Cape Town, Cape Town., Andrews JR; Division of Infectious Diseases and Geographic Medicine, Stanford University School of Medicine, Stanford, California, USA., Hatherill M; South African Tuberculosis Vaccine Initiative, Institute of Infectious Disease & Molecular Medicine and Division of Immunology, Department of Pathology, University of Cape Town, Cape Town.

Publikováno v: The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease [Int J Tuberc Lung Dis] 2019 May 01; Vol. 23 (5), pp. 571-578.

Elevated IgG Responses in Infants Are Associated With Reduced Prevalence of Mycobacterium tuberculosis Infection.

Autor: Logan E; Division of Immunology, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa., Luabeya AKK; Division of Immunology, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa.; South African Tuberculosis Vaccine Initiative (SATVI), Department of Pathology, Institute of Infectious Disease, Molecular Medicine and University of Cape Town, Cape Town, South Africa., Mulenga H; Division of Immunology, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa.; South African Tuberculosis Vaccine Initiative (SATVI), Department of Pathology, Institute of Infectious Disease, Molecular Medicine and University of Cape Town, Cape Town, South Africa., Mrdjen D; Division of Immunology, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa., Ontong C; Division of Immunology, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa.; South African Tuberculosis Vaccine Initiative (SATVI), Department of Pathology, Institute of Infectious Disease, Molecular Medicine and University of Cape Town, Cape Town, South Africa., Cunningham AF; Institutes of Immunology and Immunotherapy and Microbiology and Infection, University of Birmingham, Birmingham, United Kingdom., Tameris M; Division of Immunology, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa.; South African Tuberculosis Vaccine Initiative (SATVI), Department of Pathology, Institute of Infectious Disease, Molecular Medicine and University of Cape Town, Cape Town, South Africa., McShane H; The Jenner Institute, University of Oxford, Oxford, United Kingdom., Scriba TJ; Division of Immunology, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa.; South African Tuberculosis Vaccine Initiative (SATVI), Department of Pathology, Institute of Infectious Disease, Molecular Medicine and University of Cape Town, Cape Town, South Africa., Horsnell WGC; Division of Immunology, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa.; Institutes of Immunology and Immunotherapy and Microbiology and Infection, University of Birmingham, Birmingham, United Kingdom.; Laboratory of Molecular and Experimental Immunology and Neurogenetics, UMR 7355, Le Studium Institute for Advanced Studies, CNRS-University of Orléans, Orléans, France., Hatherill M; Division of Immunology, Institute of Infectious Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa.; South African Tuberculosis Vaccine Initiative (SATVI), Department of Pathology, Institute of Infectious Disease, Molecular Medicine and University of Cape Town, Cape Town, South Africa.

Publikováno v: Frontiers in immunology [Front Immunol] 2018 Jul 02; Vol. 9, pp. 1529. Date of Electronic Publication: 2018 Jul 02 (Print Publication: 2018).